Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Amato, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amato, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:991-992, 2002
© 2002 European Society for Medical Oncology

Editorial

Development of a prognostic model for patients with extragonadal germ-cell tumors

R. Amato

Department of Urology, Genitourinary Medical Oncology, Baylor College of Medicine, Houston, TX, USA

The first 10% of the full text of this article appears below.

Germ-cell tumors (GCTs) are unique among solid tumors in their responsiveness to therapy and in the secretion of serum tumor markers (STMs), the latter providing the clinician with an easily accessible and accurate way of following tumor response to therapy. The staging of GCTs must be clinically relevant so that patients receive the most appropriate therapy that allows for maximal cure rate with the lowest possible levels of morbidity and mortality. A major goal of the International Germ Cell Cancer Collaborative Group is the development of a universal staging system that is: (i) simple, effective and widely applicable on an . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?